Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 547 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In-vitro Clear all
Completed No phase listed Observational Accepts healthy volunteers

Analytical and Clinical Performance Testing Plan

NCT03595501
View directory record Official record
Conditions
Hematology, Hematologic Test
Interventions
Hematology Analyzer - OLO, Hematology Analyzer - Predicate
Device
Lead sponsor
Sight Diagnostics
Industry
Eligibility
3 Months and older
Enrollment
679 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 24, 2026, 6:40 PM EDT
Completed No phase listed Observational

Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage

NCT01369446
View directory record Official record
Conditions
Infertility
Interventions
Eeva System Study
Device
Lead sponsor
Progyny, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Encino, California • Palo Alto, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 24, 2026, 6:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

NCT00669669
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Filgrastim, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, O6-Benzylguanine, Plerixafor, Proton Beam Radiation Therapy, Temozolomide
Radiation · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 24, 2026, 6:40 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Er:YAG Laser in Decontamination of Dental Implants: An In-Vitro Study

NCT03100435
View directory record Official record
Conditions
Peri-Implantitis
Interventions
Er:YAG Laser, Carbon Fiber Curette
Device · Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 24, 2026, 6:40 PM EDT
Recruiting No phase listed Observational

Follicular Fluid microRNAs in Ovarian Aging and Reproduction

NCT07214246
View directory record Official record
Conditions
Ovarian Aging, In Vitro Fertilisation (IVF) Treatment, InVitro Fertilization, In Vitro Fertilization Outcome
Interventions
No Interventions
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 24, 2026, 6:40 PM EDT
Completed No phase listed Observational

Stress Level and the Relationship With IVF Outcomes.

NCT02638662
View directory record Official record
Conditions
Infertility
Interventions
Observational
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 44 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 24, 2026, 6:40 PM EDT
Recruiting Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

NCT01174108
View directory record Official record
Conditions
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Interventions
Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC
Device · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation

NCT02363426
View directory record Official record
Conditions
Infertility
Interventions
INVOcell Culture Device, IVF Incubation
Device
Lead sponsor
Invaron Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 38 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Beford, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 24, 2026, 6:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions
A2B694, A2B543, xT CDx with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 6:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

NCT02714036
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ibudilast
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Patchogue, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 24, 2026, 6:40 PM EDT
Completed Not applicable Interventional Results available

Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19

NCT04662671
View directory record Official record
Conditions
COVID19
Interventions
RD-X19
Device
Lead sponsor
EmitBio Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 24, 2026, 6:40 PM EDT
Terminated Not applicable Interventional

Oral Versus Intravenous Acetaminophen for Postoperative Pain Control

NCT04662567
View directory record Official record
Conditions
Postoperative Pain, IVF
Interventions
acetaminophen
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 24, 2026, 6:40 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation

NCT04401631
View directory record Official record
Conditions
Allergy, Allergic Asthma, Allergy to Cats, Allergy to House Dust, Allergy to Dog Dander (Finding), Allergy Mold, Allergy Cockroach
Interventions
Blood Collection
Device
Lead sponsor
Abionic SA
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 24, 2026, 6:40 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

NCT05736731
View directory record Official record
Conditions
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions
A2B530, xT-Onco with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 24, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Iron Supplements on the Growth of Enteric Pathogens

NCT05762380
View directory record Official record
Conditions
Iron-deficiency, Iron Deficiency Anaemia Due to Dietary Causes, Iron Deficiency Anemia Treatment, Iron Deficiency Anemia
Interventions
Ferrous sulfate, Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 24, 2026, 6:40 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?

NCT00804960
View directory record Official record
Conditions
Infertility
Interventions
Letrozole, Std IVF Protocol
Drug
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 38 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 24, 2026, 6:40 PM EDT
Terminated No phase listed Observational

Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy

NCT01140776
View directory record Official record
Conditions
Breast Neoplasms, Breast Diseases
Interventions
Not listed
Lead sponsor
Sysmex America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Tucson, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 24, 2026, 6:40 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00003727
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, recombinant interferon alfa, sargramostim, therapeutic autologous lymphocytes, carmustine, cyclophosphamide, etoposide, gemcitabine hydrochloride, melphalan, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 24, 2026, 6:40 PM EDT
Completed Not applicable Interventional

in Vitro Fertilization (IVF) Media Protein and Live Birth Rates

NCT00708383
View directory record Official record
Conditions
Infertility, Pregnancy Outcome, Live Birth, In Vitro Fertilization
Interventions
10% SSS embryo culture medium protein supplementation, 0.5% HSA embryo culture medium protein supplementation
Other
Lead sponsor
Texas Health Resources
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 24, 2026, 6:40 PM EDT
Completed No phase listed Observational

Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass

NCT01352143
View directory record Official record
Conditions
Cardiopulmonary Bypass
Interventions
Recombinant activated factor VII, Prothrombin Complex Concentrate
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 24, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Osteogenic Profiling of Tissue From Children With Craniosynostosis

NCT00773643
View directory record Official record
Conditions
Craniosynostosis
Interventions
biopsy
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
2 Months to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 24, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

NCT07542041
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Lesions Located at the Body or the Tail
Interventions
ARTIDIS ART-1 Device
Device
Lead sponsor
ARTIDIS AG
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 24, 2026, 6:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers of Trained Immunity Following MMR Vaccination

NCT04646239
View directory record Official record
Conditions
Covid19
Interventions
Heterologous stimuli, Neutralization assay
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 24, 2026, 6:40 PM EDT
Terminated Phase 2 Interventional

Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

NCT00002778
View directory record Official record
Conditions
Leukemia
Interventions
sargramostim, therapeutic allogeneic lymphocytes, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 24, 2026, 6:40 PM EDT